Literature DB >> 10600269

The cannabinoid agonist HU 210 modifies rat behavioural responses to novelty and stress.

D Giuliani1, F Ferrari, A Ottani.   

Abstract

Experiments were performed on groups of rats after acute and sub-chronic treatment (once daily for 9 days) with the cannabinoid agonist HU 210 (25-100 microg kg(-1), i.p.) as well as 24 h and 7 days after the last drug injection. The animals underwent three behavioural tests in novel environments. In the observation cages (Test 1), rat locomotor activity was found to be dose-dependently reduced after acute and sub-chronic treatment at all doses and virtually unchanged during abstinence; grooming was potently inhibited by acute treatment but potentiated by the sub-chronic one at doses of 50 and 100 microg kg(-1), the effect of the higher dose persisting after 24 h and 7 days abstinence. Vocalization in animals in response to a tactile stimulus was highest after HU 210 at 100 microg kg(-1) in all experimental modes except after 7 days abstinence. In the X-maze (Test 2), sub-chronic HU 210 dose- dependently enhanced rat natural aversion for open arms, and this behaviour persisted during abstinence after the highest dose. Grooming in the X-maze was completely absent in rats acutely injected with HU 210 but potentiated in those sub-chronically treated or abstinent. In the swimming test (Test 3) rats sub-chronically treated at 50 and 100 pg kg(-1) displayed relevant wall-hugging and the same occurred 24 h after last injection. On the whole, our results are indicative of an anxiogenic-like effect of sub-chronic HU 210 at high doses and reflect the persistence of enhanced emotional response to novel environments when the treatment is discontinued. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10600269     DOI: 10.1006/phrs.1999.0560

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  6 in total

1.  Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats.

Authors:  Charlotte Klein; Emily Karanges; Adena Spiro; Alexander Wong; Jarrah Spencer; Thanh Huynh; Nathan Gunasekaran; Tim Karl; Leonora E Long; Xu-Feng Huang; Kelly Liu; Jonathon C Arnold; Iain S McGregor
Journal:  Psychopharmacology (Berl)       Date:  2011-06-11       Impact factor: 4.530

2.  CB(1) cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction.

Authors:  Jens A Wagner; Kai Hu; Jan Karcher; Johann Bauersachs; Andreas Schäfer; Martin Laser; Hong Han; Georg Ertl
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

3.  Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats.

Authors:  Daina Economidou; Laura Mattioli; Carlo Cifani; Marina Perfumi; Maurizio Massi; Vincenzo Cuomo; Luigia Trabace; Roberto Ciccocioppo
Journal:  Psychopharmacology (Berl)       Date:  2005-10-29       Impact factor: 4.415

4.  Behavioral and neurochemical changes in mesostriatal dopaminergic regions of the rat after chronic administration of the cannabinoid receptor agonist WIN55,212-2.

Authors:  Eleni Fanarioti; Maria Mavrikaki; George Panagis; Ada Mitsacos; George G Nomikos; Panagiotis Giompres
Journal:  Int J Neuropsychopharmacol       Date:  2014-12-07       Impact factor: 5.176

5.  Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission.

Authors:  J Haller; F Mátyás; K Soproni; B Varga; B Barsy; B Németh; E Mikics; T F Freund; N Hájos
Journal:  Eur J Neurosci       Date:  2007-04       Impact factor: 3.386

Review 6.  Endocannabinoid system and synaptic plasticity: implications for emotional responses.

Authors:  María-Paz Viveros; Eva-María Marco; Ricardo Llorente; Meritxell López-Gallardo
Journal:  Neural Plast       Date:  2007       Impact factor: 3.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.